Level Bio AB (publ) (FRA:4MB)

Market Cap	1.66M -30.8%
Revenue (ttm)	3.10M +14.3%
Net Income	429.58K
EPS	n/a
Shares Out	n/a
PE Ratio	3.85
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0145
Previous Close	0.0140
Day's Range	0.0145 - 0.0145
52-Week Range	0.0105 - 0.0315
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 23, 2026

About Level Bio AB

Level Bio AB (publ) manufactures and distributes cutting-edge solutions in the Nordic region and internationally. It develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to Level Bio AB (publ) in May 2024. Level Bio AB (publ) was incorporated in 1998 and is headquartered in Stockholm, Sweden.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1998
• Employees: 10
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4MB

Financial Performance

In 2025, Level Bio AB's revenue was 32.36 million, an increase of 28.95% compared to the previous year's 25.10 million. Losses were -3.54 million, -55.04% less than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error